Abstract
Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.
Original language | English (US) |
---|---|
Pages (from-to) | 1058-1059 |
Number of pages | 2 |
Journal | Leukemia |
Volume | 33 |
Issue number | 4 |
DOIs |
|
State | Published - Apr 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Correction : Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329). / Chim, C. S.; Kumar, Shaji K; Orlowski, R. Z.; Cook, G.; Richardson, P. G.; Gertz, Morie; Giralt, S.; Mateos, M. V.; Leleu, X.; Anderson, K. C.
In: Leukemia, Vol. 33, No. 4, 01.04.2019, p. 1058-1059.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Correction
T2 - Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)
AU - Chim, C. S.
AU - Kumar, Shaji K
AU - Orlowski, R. Z.
AU - Cook, G.
AU - Richardson, P. G.
AU - Gertz, Morie
AU - Giralt, S.
AU - Mateos, M. V.
AU - Leleu, X.
AU - Anderson, K. C.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.
AB - Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.
UR - http://www.scopus.com/inward/record.url?scp=85062627472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062627472&partnerID=8YFLogxK
U2 - 10.1038/s41375-019-0410-3
DO - 10.1038/s41375-019-0410-3
M3 - Comment/debate
C2 - 30842604
AN - SCOPUS:85062627472
VL - 33
SP - 1058
EP - 1059
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 4
ER -